සාමාජික තොරතුරු

Dr Marta Morales Ballús
ස්පාඤ්ඤයේ
කණ්ඩායම

Dr Jaume Català Mora
ස්පාඤ්ඤයේ

Dr Elisa Carreras
ස්පාඤ්ඤයේ

Dr Itziar Alonso
ස්පාඤ්ඤයේ

Dr Isabel Ayet
ස්පාඤ්ඤයේ

Dr Ester Casas
ස්පාඤ්ඤයේ

Optometrist Ana Díaz
ස්පාඤ්ඤයේ

Dr Jesús Díaz
ස්පාඤ්ඤයේ

Optometrist Enric Puigventos
ස්පාඤ්ඤයේ

Optometrist Carles Fresno
ස්පාඤ්ඤයේ

Dr Carmen García Vicuña
ස්පාඤ්ඤයේ

Dr Hugo Gonzalez
ස්පාඤ්ඤයේ

Optometrist Enrique Jimenez
ස්පාඤ්ඤයේ

Dr Ana Llorca
ස්පාඤ්ඤයේ

Dr Antonio Federico Martinez Monstseny
ස්පාඤ්ඤයේ

Dr Joan Prat
ස්පාඤ්ඤයේ

Dr Gemma Romeu
ස්පාඤ්ඤයේ

Dr Alicia Serra
ස්පාඤ්ඤයේ

Optometrist Simone Suh
ස්පාඤ්ඤයේ

Dr Mariona Vidal
ස්පාඤ්ඤයේ

Optometrist Begoña Yeste
ස්පාඤ්ඤයේ

Dr Núria Planas
ස්පාඤ්ඤයේ
HCP මධ්යස්ථානය

අමතන්න
Hospital Sant Joan de Déu, Spain
සායනික පරීක්ෂණ

A Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Venglustat in Late-onset GM2 Gangliosidosis (Tay-Sachs Disease and Sandhoff Disease) Together With a Separate Basket for Juvenile/Adolescent Late-onset GM2 Gangliosidosis and Ultra-rare Diseases Within the Same and Similar Glucosylceramide-based Sphingolipid Pathway

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

A Phase 2, Randomized, Open-Label, 12-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult Participants with PMM2-CDG

A Phase 2/3, Open-label, Historical-controlled, Single-arm, Multicenter Study to Evaluate the Efficacy, Pharmacokinetics, Pharmacodynamics, and Safety of Ravulizumab in Children and Adolescents With Aquaporin-4 antibody Positive (AQP4-Ab [+]) Neuromyelitis Optica Spectrum Disorder (NMOSD)

A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Therapy

A Phase 3, multicenter, randomized, evaluator-blinded clinical trial to assess the safety and efficacy of Clobetasol propionate ophthalmic nanoemulsion, 0.05% compared to Prednisolone acetate, 1% in the treatment of inflammation after cataract surgery in pediatric population 0 to 3 years of age (CLOSE-3)”. CLOBOF3-17IA03 (CLOSE-3).

MyopiaX Treatment for the Reduction of Myopia Progression in Children and Adolescents: Safety and Efficacy Investigation